ZBIO — Zenas Biopharma Income Statement
0.000.00%
Last trade - 00:00- $2.18bn
- $1.96bn
- $5.00m
Annual income statement for Zenas Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 0 | 50 | 5 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Unusual Expense / Income | |||
| Total Operating Expenses | 76.2 | 87.1 | 169 |
| Operating Profit | -76.2 | -37.1 | -164 |
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -119 | -36.8 | -157 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -119 | -37.1 | -157 |
| Net Income Before Extraordinary Items | |||
| Net Income | -119 | -37.1 | -157 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -119 | -37.1 | -157 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -2.97 | -0.682 | -11.9 |
| Dividends per Share |